


ABSTRACT

In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of leukemia comprising at least one active compound of formula (I):



(I)

and a Bcr-Abl tyrosine kinase inhibitor, and a method of treating a patient having leukemia comprising at least one active compound of formula (I), as defined above, and a Bcr-Abl tyrosine kinase inhibitor.